Menu
Annual · values20252024202320222021202020192018
Operating Cash Flow192.84 M USD48.80 M USD-13.03 M USD-45.82 M USD-28.86 M USD-30.27 M USD-32.29 M USD-25.98 M USD
Depreciation & Amortization27.18 M USD19.76 M USD8.18 M USD3.48 M USD1.82 M USD1.58 M USD1.22 M USD769000 USD
Stock-Based Compensation36.86 M USD33.22 M USD19.79 M USD10.32 M USD6.88 M USD2.41 M USD854000 USD144000 USD
Capital Expenditures59.25 M USD129.74 M USD151.85 M USD11.91 M USD3.52 M USD455000 USD165000 USD418000 USD
Cash Flow from Investing-59.25 M USD-129.30 M USD-193.95 M USD54.51 M USD29.27 M USD-41.60 M USD-60.50 M USD12.31 M USD
Cash Flow from Financing16.86 M USD22.87 M USD400.42 M USD167.93 M USD1.39 M USD75.55 M USD92.72 M USD22.06 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow133.59 M USD-80.94 M USD-164.88 M USD-57.72 M USD-32.38 M USD-30.72 M USD-32.45 M USD-26.40 M USD

TransMedics Group Inc. is a commercial-stage medical technology company focused on advancing organ transplant therapy for patients with end-stage organ failure. It develops and commercializes the Organ Care System (OCS), a portable platform that preserves, optimizes, and monitors donor organs in near-physiologic conditions outside the body, overcoming limitations of traditional cold storage methods. The OCS supports multiple organ types, enabling improved transplant outcomes through real-time assessment and maintenance during transport. TransMedics Group Inc. operates in the health technology sector, specifically medical specialties, serving transplant centers and healthcare providers to expand access to viable organs. The company enhances organ utilization rates and logistics, including aviation partnerships for nationwide transport networks. Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics Group Inc. plays a critical role in transforming solid organ transplantation by integrating innovative perfusion technology with comprehensive organ recovery services.